C07K 16/289
Against cd45
Official title: {against CD45}
C07K16/289 (Against cd45) appears on 98 US grants and 215 published applications in this corpus.
Search patents in C07K- Granted patents
- 98
- Published applications
- 215
- Assignees
- 111
- Inventors
- 399
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 5 | 0 |
| 2001 | 1 | 1 |
| 2002 | 4 | 7 |
| 2003 | 0 | 10 |
| 2004 | 2 | 3 |
| 2005 | 5 | 5 |
| 2006 | 0 | 5 |
| 2007 | 3 | 0 |
| 2008 | 1 | 5 |
| 2009 | 1 | 4 |
| 2010 | 2 | 1 |
| 2011 | 0 | 1 |
| 2012 | 2 | 2 |
| 2013 | 0 | 0 |
| 2014 | 1 | 3 |
| 2015 | 0 | 1 |
| 2016 | 1 | 8 |
| 2017 | 3 | 10 |
| 2018 | 1 | 11 |
| 2019 | 7 | 14 |
| 2020 | 9 | 16 |
| 2021 | 4 | 22 |
| 2022 | 8 | 20 |
| 2023 | 7 | 16 |
| 2024 | 7 | 16 |
| 2025 | 12 | 16 |
| 2026 | 4 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-CD45 antibody drug conjugates and uses thereof1 Sep 2026US 12,723,097 B2Regeneron Pharmaceuticals, Inc.
- Stabilized radiolabeled anti-CD45 immunoglobulin compositions18 Aug 2026US 12,708,678 B2Actinium Pharmaceuticals, Inc.
- Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof21 Apr 2026US 12,605,472 B2Actinium Pharmaceuticals, Inc.
- Methods of use of anti-CD45 antibodies and conjugates thereof10 Mar 2026US 12,570,756 B2Regeneron Pharmaceuticals, Inc.
- Conditioning agents for use in allogeneic hematopoietic stem cell transplantation16 Dec 2025US 12,496,303 B2Washington University
- Trogocytosis in cancer cells and methods for treating cancer related thereto17 Sep 2026US 2026/0274990 A1Arizona Board of Regents on Behalf of the University of Arizona
- Developing an anti-human cd45 imaging probe for noninvasive detection of human immune cells10 Sep 2026US 2026/0263647 A1Dana-Farber Cancer Institute, Inc.
- Anti-cd45 antibody-drug conjugate pharmaceutical compositions6 Aug 2026US 2026/0224729 A1Regeneron Pharmaceuticals, Inc.
- Epitope editing and multi-specific immunce-cell engager therapy and methods of use30 Jul 2026US 2026/0217848 A1The Trustees of the University of Pennsylvania
- Affinity and functional based screening of t cell receptor repertoire using three-dimensional shaped particles30 Jul 2026US 2026/0218282 A1The Regents of the University of California
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005